Puma Biotechnology (PBYI) Stock Price, News & Analysis

Company Overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Key Stats

• Today's Range: $3.42 to $3.49
• 50-Day Range: $2.76 to $3.62
• 52-Week Range: $2.23 to $6.06
• Volume: 15,763 shs
• Average Volume: 442,675 shs
• Market Capitalization: $167.83 million
• P/E Ratio: 7.05
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

Puma Biotechnology Stock Analysis - MarketRank™

Puma Biotechnology scored higher than 81% of companies evaluated by MarketBeat, and ranked 174th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Puma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Puma Biotechnology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 22.58%

Earnings Growth

Earnings for Puma Biotechnology are expected to grow by 22.58% in the coming year, from $0.31 to $0.38 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Puma Biotechnology is 7.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.61.

Price to Earnings Ratio vs. Sector

The P/E ratio of Puma Biotechnology is 7.23, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.71.

Price to Book Value per Share Ratio

Puma Biotechnology has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.13% of the float of Puma Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Puma Biotechnology has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Puma Biotechnology has recently increased by 2.93%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Puma Biotechnology does not currently pay a dividend.

Dividend Growth

Puma Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.13% of the float of Puma Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Puma Biotechnology has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Puma Biotechnology has recently increased by 2.93%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.06

News Sentiment

Puma Biotechnology has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Puma Biotechnology this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for PBYI on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $136,326.00 in company stock.

Percentage Held by Insiders

23.70% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PBYI Stock Analysis - Frequently Asked Questions

How have PBYI shares performed this year?

Puma Biotechnology's stock was trading at $3.05 at the beginning of the year. Since then, PBYI stock has increased by 13.8% and is now trading at $3.47.
View the best growth stocks for 2025 here.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) announced its quarterly earnings results on Thursday, February, 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.10 by $0.29. The biopharmaceutical company earned $59.10 million during the quarter, compared to analyst estimates of $52.50 million. Puma Biotechnology had a net margin of 9.56% and a trailing twelve-month return on equity of 41.60%.

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's top institutional shareholders include Acorn Capital Advisors LLC (4.99%), Millennium Management LLC (3.86%), Renaissance Technologies LLC (3.58%) and Eversept Partners LP (2.03%). Insiders that own company stock include Alan H Auerbach, Maximo F Nougues, Jeffrey Jerome Ludwig, Alvin F Wong, Douglas M Hunt, Michael Patrick Miller and Troy Edward Wilson.
View institutional ownership trends.

How do I buy shares of Puma Biotechnology?

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Puma Biotechnology investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), Humana (HUM), American Water Works (AWK) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 3/25/2025
• Next Earnings (Estimated): 5/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PBYI
• CIK: 1401667
• Web: www.pumabiotechnology.com
• Phone: (424) 248-6500
• Fax: 424-248-6501
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $7.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +101.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.61
• Trailing P/E Ratio: 7.23
• Forward P/E Ratio: 11.19
• P/E Growth: N/A
• Net Income: $21.59 million
• Net Margins: 9.56%
• Pretax Margin: 10.13%
• Return on Equity: 41.60%
• Return on Assets: 10.71%

Debt

• Debt-to-Equity Ratio: 0.46
• Current Ratio: 1.42
• Quick Ratio: 1.40

Sales & Book Value

• Annual Sales: $230.47 million
• Price / Sales: 0.75
• Cash Flow: $0.83 per share
• Price / Cash Flow: 4.19
• Book Value: $1.12 per share
• Price / Book: 3.10

Miscellaneous

• Outstanding Shares: 49,611,000
• Free Float: 37,454,000
• Market Cap: $172.15 million
• Optionable: Optionable
• Beta: 1.33